secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2023-03-27T23:59:59+00:00
Accession:  0001576885-23-000013
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen reports FY2022 net loss $42.9M; Phase 1 ACU193 enrollment completed, topline Q3 2023
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities of $193.4M as of Dec 31, 2022, expected to fund operations through 2025.
- Net loss of $42.9M for FY2022 vs $100.6M in 2021 (which included $81.2M non-cash charge).
- Phase 1 INTERCEPT-AD trial of ACU193 in early Alzheimer's completed enrollment Feb 2023; topline data expected Q3 2023.
- Protocol amendment reduced cohort 7 dose to 25 mg/kg Q2W after blinded PK/SA, 2 asymptomatic ARIA-E cases noted.
- FDA granted Fast Track designation for ACU193 in Oct 2022; Derrell Porter, M.D. joined board in Jan 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000157688523000013/0001576885-23-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000157688523000013/abos-20230327.htm
  HTML page:      https://secwatch.observer/filing/0001576885-23-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer